Who is sponsoring NCT06058520?

NCT06058520 is sponsored by University of Minnesota.

What drugs are being tested in NCT06058520?

Interventions in NCT06058520: Fecal Microbiota - lyophilized, Placebo drug.

What condition does NCT06058520 study?

NCT06058520 studies Hidradenitis Suppurativa.

Is NCT06058520 still recruiting?

NCT06058520 is currently recruiting now. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT06058520

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Recruiting now EARLY_PHASE1 Last updated 17 February 2026

What this trial tests

EARLY_PHASE1 trial testing Fecal Microbiota - lyophilized in Hidradenitis Suppurativa in 16 participants. Currently enrolling.

Timeline

1 October 2023

Primary endpoint
1 September 2026

1 September 2026

Quick facts

Lead sponsor	University of Minnesota
Phase	EARLY_PHASE1
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	16
Start date	1 October 2023
Primary completion	1 September 2026
Estimated completion	1 September 2026
Sites	1 location across United States

Drugs / interventions tested

Fecal Microbiota - lyophilized — full drug profile →
Placebo drug — full drug profile →

Conditions studied

Hidradenitis Suppurativa — all drugs for Hidradenitis Suppurativa →

Sponsor

University of Minnesota

Who can join

18 and older, any sex, with Hidradenitis Suppurativa. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HS is relatively common in the United States with a prevalence of 0.1-1.0%. 1 HS has a dramatic impact on quality of life, significantly more so than other chronic skin diseases, such as psoriasis or atopic dermatitis (AD). HS also has a large economic impact, due to frequent emergency department and inpatient care utilization, and re-hospitalization rates similar to congestive heart failure. Unfortunately, few treatment options are effective. There are currently three FDA-approved treatments for HS, including adalimumab, secukinumab, and bimekizumab, each with only 40- 60% respond to treatment and over 50% lose response within one year . The overarching goal of this pilot study is to investigate the central hypothesis that oral microbiota transplant therapy(MTT) alters the gut microbiome in patients with Hidradenitis Suppurativa (HS), influencing cutaneous microbiota via systemically absorbed gut-derived metabolites.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Meta-inflammation in Hidradenitis suppurativa: from pathogenic evidence to therapeutic approaches
Moltrasio C, Khan A, Ahmad N, Malik M, et al ·

Verify or expand the search:

Other recruiting trials for Hidradenitis Suppurativa

Currently open trials in the same condition.

NCT07244263 — A Study of Zasocitinib in Adults With Hidradenitis Suppurativa · Phase 2 · recruiting
NCT07225569 — A Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Sup · Phase 2 · recruiting
NCT07243782 — Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cose · recruiting
NCT07282015 — Real-world Secukinumab Outcomes in Canadian HS Patients · recruiting
NCT07228390 — A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps · Phase 2 · recruiting

Other University of Minnesota trials

Trials by the same sponsor.

NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06058520 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06058520.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing